Dopamine Agonist News and Research

RSS
Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

New experimental treatment for Tourette's syndrome

New experimental treatment for Tourette's syndrome

FDA approves skin patch designed to treat symptoms of early Parkinson's disease

FDA approves skin patch designed to treat symptoms of early Parkinson's disease

Phase III data on Safinamide in Parkinson's disease

Phase III data on Safinamide in Parkinson's disease

Jefferson participates in global study to extend effectiveness of drug for Parkinson's

Jefferson participates in global study to extend effectiveness of drug for Parkinson's

Therapy for restless legs may trigger compulsive gambling

Therapy for restless legs may trigger compulsive gambling

New guidelines for diagnosis and treatment of Parkinson disease

New guidelines for diagnosis and treatment of Parkinson disease

Parkinson's dark period can be minimized or alleviated with the right kind of care

Parkinson's dark period can be minimized or alleviated with the right kind of care

Gambling and sex addiction caused by Parkinson's drug

Gambling and sex addiction caused by Parkinson's drug

Dopamine agonist therapy for Parkinson's disease may lead to problem gambling

Dopamine agonist therapy for Parkinson's disease may lead to problem gambling

Clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease

Clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease

Clinical study compares treatments in early Parkinson's disease

Clinical study compares treatments in early Parkinson's disease

Antipsychotic compound bifeprunox worth USD 1 billion per year to Solvay and Wyeth

Antipsychotic compound bifeprunox worth USD 1 billion per year to Solvay and Wyeth

FDA approves new breakthrough Parkinson's drug

FDA approves new breakthrough Parkinson's drug

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.